Section 2. Patientsneeds/epidemiology
Section 3. Stakeholdersstrategies
3.1 Pharmaceutical sector
3.2 Biotechnology sector
3.3 Patient associations/Consumer associations
4.1 Public policies on orphan drugs (definitions, results)
4.2 Orphan drug status initiatives in the different countries
4.3 Comparative results of the different policies and lessons for Europe
5.1 Current European Policy
5.2 R&D policy
5.3 Industrial and other market regulation policies
5.4 Development and cooperation policies
6.1 Orphan drugs definition
6.2 Orphan drugs legal status
6.3 Incentives to encourage efficient orphan drugs supply
6.4 Industrial policies
6.5 R&D policies
6.6 Development and cooperation policies